Achillion Pharmaceuticals, located in New Haven, Connecticut, is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease – HIV, hepatitis and resistant bacterial infections. Achillion’s drug development pipeline is led by elvucitabine (Beta-L-Fd4C or ACH-126,443), which is currently in late-stage Phase 2 clinical trials for the treatment of patients infected with HIV. In addition, Achillion’s late-stage pre-clinical candidate for the potential treatment of HCV infection, ACH-806, is anticipated to begin human clinical testing mid-2005.
Avalon Pharmaceuticals, located in Gaithersburg, Maryland, utilizes unique and proprietary forward chemical genomics-based methods to accelerate the discovery of novel targets and drugs. Avalon's unique capabilities in cytogenetics and gene expression analysis allow the company to rapidly discover and validate novel oncology targets. For the discovery of small molecules, Avalon utilizes a comprehensive systems approach, enabling more informed decisions at earlier stages in the drug discovery process. The AvalonRx™ drug discovery platform allows for the rapid identification of lead compounds through an enriched understanding of the mechanism of action within diseased cells, leading to accelerated medicinal chemistry driven lead optimization programs and clinical development. This revolutionary systems approach is applicable across multiple disease areas. Currently, Avalon is focusing its efforts to produce the next generation of cancer medicines.
Corixa Corporation (NASD: CRXA), based in Seattle, WA, is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to or through late stage clinical trials. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa™ technology with the goal of making its potential products available to patients around the world.
ISTA Pharmaceuticals (NASD: ISTA), based in Irvine, CA, is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products for serious conditions of the eye. ISTA has two approved products, IstalolTM (for the treatment of glaucoma) and Vitrase® (for use as a "spreading agent"). The company launched IstalolTM in July 2004 and is currently launching Vitrase®. ISTA has two pending NDAs with the FDA: Vitrase® (for the treatment of vitreous hemorrhage) and XibromTM (for the treatment of ocular inflammation, eye pain and photophobia following cataract surgery). ISTA has other prescription products under development, including ecabet sodium, for the treatment of dry eye, and Caprogel® for the treatment of hyphema. In order to further build its pipeline as a specialty pharmaceutical company, ISTA expects to acquire complementary products in ophthalmology, either already marketed or in late-stage development.
Lumenos, based in Alexandria, Virginia, is a pioneer in the Consumer-Driven Health Care industry. The company’s vision is to foster health care that actually cares about health. Lumenos’ award winning approach empowers consumers with health accounts (including Health Reimbursement Accounts and Health Savings Accounts), information, services and incentives to become better informed about their health and engage in health-promoting behaviors. Lumenos’ goal is to improve consumers’ health outcomes, and by doing so, to achieve long-term cost efficiency for employers. Lumenos plans are available in all 50 states and are offered by many Fortune 500 companies.
Neuronetics ], based in Malvern, PA, is an emerging medical device company focused on successfully developing and commercializing innovative, non-invasive therapies to treat psychiatric and neurological disorders using a technology called transcranial magnetic stimulation (TMS). TMS involves the use of very short pulses of magnetic energy to stimulate nerve cells in the brain. Neuronetics’ advanced TMS technology is currently under investigation for the treatment of major depression in a series of integrated clinical trials. These trials will evaluate its safety and ability to improve mood in major depression patients. Information from these trials will be submitted to the US Food and Drug Administration (FDA) to support clearance, which would ultimately allow US physicians to use Neuronetics’ technology to treat patients with symptoms of depression.
PneumRx, based in Mountain View, CA, develops minimally invasive medical devices for interventional pulmonary and thoracic surgery. The company is initially focused on devices and related technologies for chronic obstructive pulmonary disease and lung cancer.
Prolong Pharmaceuticals, based in Califon, NJ, is a biopharmaceutical company whose core technology is an FDA approved delivery system for protein-based biopharmaceuticals, known as PEGylation. This process involves the chemical attachment of polyethylene glycol ("PEG") to a therapeutic protein. The result is a product that has significantly improved therapeutic properties, affords better patient compliance and reduced side effects. Prolong will develop long-acting biopharmaceuticals through its own research and by collaboration. These products may be sold by the company or licensed to third parties in other geographic areas.
Remon Medical Technologies, Inc. commercializes smart, miniature implants that enable physicians to assess and treat a variety of medical conditions in a non- invasive manner. The Company's enabling technology utilizes wireless communications to exchange energy and data with miniature devices placed deep inside the body, in order to either monitor a variety of physiological parameters or to stimulate tissues and organs or to activate other devices, creating therapeutic responses. Remon's unique platform has broad applications for patient management, post-operative monitoring, nerve and tissue stimulation, and local drug delivery/release.
Scandius BioMedical, Inc., based in Littleton, MA, is a privately held medical device company that designs, manufactures and markets products for the orthopedic sports medicine market. The company was founded in 2000 and is focused on accelerating innovative solutions for minimally invasive orthopedic sports medicine procedures. Scandius recently launched the StratisTM ST ACL Reconstruction System and Femoral Fixation Implant, a revolutionary technology addressing arthroscopic reconstruction of the torn anterior cruciate ligament. The company’s development plan includes fixation technologies in several other high-volume procedural areas.
Scynexis is a drug discovery and development company headquartered in Research Triangle Park, North Carolina, with its European operations, SCYNEXIS Europe Ltd., located near Cambridge, England. By combining its chemists’ expertise with proprietary KIT™ Kinase Inhibitor Technology, MEDCHEM-FACTORYTM technology and Hit Explorer Operating System (HEOS®), SCYNEXIS provides improved speed and productivity in the chemical validation of drug targets. SCYNEXIS also offers novel hit generation compounds, hit explosion and lead optimization services as well as process optimization, purification and analysis of compound libraries, in vitro ADMET, the production of clinical samples in its GMP facility and radiochemistry synthesis services.
Spinal Concepts, based in Austin, Texas, develops and markets technologically advanced spinal implants used in the treatment of degenerative disc disease, spinal injury and deformity. The company has a diverse line of products to address clinical needs in all areas of the spine. Spinal Concepts is currently in advanced clinical testing with a next generation interbody fusion device that allows surgeons the ability to adjust the disc height and the angle of curvature of the spine. There are also other innovative spinal products currently in development. In June 2003, Abbott Laboratories announced it was acquiring Spinal Concepts for $170 million in cash plus additional milestone payments of up to $40 million. Please see the press release for details.